Cargando…
Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
CONTEXT: The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. OBJECTIVE: We c...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856268/ https://www.ncbi.nlm.nih.gov/pubmed/36694808 http://dx.doi.org/10.1210/jendso/bvad002 |
_version_ | 1784873578491019264 |
---|---|
author | Fujita, Yasunori Kamitani, Fumika Yamamoto, Masaaki Fukuoka, Hidenori Hirota, Yushi Nishiyama, Nobuharu Goda, Naho Okada, Yuko Inaba, Yuiko Nakajima, Hiroki Kurematsu, Yukako Kanie, Keitaro Shichi, Hiroki Urai, Shin Suzuki, Masaki Yamamoto, Naoki Bando, Hironori Iguchi, Genzo Suto, Hirotaka Funakoshi, Yohei Kiyota, Naomi Takahashi, Yutaka Ogawa, Wataru |
author_facet | Fujita, Yasunori Kamitani, Fumika Yamamoto, Masaaki Fukuoka, Hidenori Hirota, Yushi Nishiyama, Nobuharu Goda, Naho Okada, Yuko Inaba, Yuiko Nakajima, Hiroki Kurematsu, Yukako Kanie, Keitaro Shichi, Hiroki Urai, Shin Suzuki, Masaki Yamamoto, Naoki Bando, Hironori Iguchi, Genzo Suto, Hirotaka Funakoshi, Yohei Kiyota, Naomi Takahashi, Yutaka Ogawa, Wataru |
author_sort | Fujita, Yasunori |
collection | PubMed |
description | CONTEXT: The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. OBJECTIVE: We comparatively analyzed the clinical features of this combination and each individual ICI-induced endocrinopathy. METHODS: We reported 3 cases that we encountered and reviewed previously reported cases of patients with combined hypophysitis and T1DM due to ICIs. RESULTS: Anti-programmed cell death-1 (anti-PD-1) antibodies were prescribed to all 3 cases. The duration from ICI initiation to the onset of endocrine disease was 12 to 48 weeks. Several human leukocyte antigen (HLA) haplotypes that have disease susceptibility to hypophysitis were detected in all 3 patients. With the 17 previously reported cases, combined endocrinopathies were more common in men (85%). The onset age was in the 60s for both combined and single endocrinopathies. Anti-PD-1 antibodies were used in most of the cases (90%). The time from ICI initiation to the onset of endocrinopathies was 24 (8-76) weeks for hypophysitis and 32 (8-76) weeks for T1DM in patients with combined endocrinopathies, which was not significantly different from that for each single endocrinopathy. CONCLUSION: We presented 3 cases of patients with combined endocrinopathies of hypophysitis and T1DM that may have been caused by anti-PD-1 antibodies. There was no difference in the time from ICI initiation to the onset of endocrinopathies between combined and single endocrinopathies. Further case accumulation and pathogenic investigations are required. |
format | Online Article Text |
id | pubmed-9856268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98562682023-01-23 Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors Fujita, Yasunori Kamitani, Fumika Yamamoto, Masaaki Fukuoka, Hidenori Hirota, Yushi Nishiyama, Nobuharu Goda, Naho Okada, Yuko Inaba, Yuiko Nakajima, Hiroki Kurematsu, Yukako Kanie, Keitaro Shichi, Hiroki Urai, Shin Suzuki, Masaki Yamamoto, Naoki Bando, Hironori Iguchi, Genzo Suto, Hirotaka Funakoshi, Yohei Kiyota, Naomi Takahashi, Yutaka Ogawa, Wataru J Endocr Soc Clinical Research Article CONTEXT: The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. OBJECTIVE: We comparatively analyzed the clinical features of this combination and each individual ICI-induced endocrinopathy. METHODS: We reported 3 cases that we encountered and reviewed previously reported cases of patients with combined hypophysitis and T1DM due to ICIs. RESULTS: Anti-programmed cell death-1 (anti-PD-1) antibodies were prescribed to all 3 cases. The duration from ICI initiation to the onset of endocrine disease was 12 to 48 weeks. Several human leukocyte antigen (HLA) haplotypes that have disease susceptibility to hypophysitis were detected in all 3 patients. With the 17 previously reported cases, combined endocrinopathies were more common in men (85%). The onset age was in the 60s for both combined and single endocrinopathies. Anti-PD-1 antibodies were used in most of the cases (90%). The time from ICI initiation to the onset of endocrinopathies was 24 (8-76) weeks for hypophysitis and 32 (8-76) weeks for T1DM in patients with combined endocrinopathies, which was not significantly different from that for each single endocrinopathy. CONCLUSION: We presented 3 cases of patients with combined endocrinopathies of hypophysitis and T1DM that may have been caused by anti-PD-1 antibodies. There was no difference in the time from ICI initiation to the onset of endocrinopathies between combined and single endocrinopathies. Further case accumulation and pathogenic investigations are required. Oxford University Press 2023-01-06 /pmc/articles/PMC9856268/ /pubmed/36694808 http://dx.doi.org/10.1210/jendso/bvad002 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research Article Fujita, Yasunori Kamitani, Fumika Yamamoto, Masaaki Fukuoka, Hidenori Hirota, Yushi Nishiyama, Nobuharu Goda, Naho Okada, Yuko Inaba, Yuiko Nakajima, Hiroki Kurematsu, Yukako Kanie, Keitaro Shichi, Hiroki Urai, Shin Suzuki, Masaki Yamamoto, Naoki Bando, Hironori Iguchi, Genzo Suto, Hirotaka Funakoshi, Yohei Kiyota, Naomi Takahashi, Yutaka Ogawa, Wataru Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors |
title | Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors |
title_full | Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors |
title_fullStr | Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors |
title_full_unstemmed | Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors |
title_short | Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors |
title_sort | combined hypophysitis and type 1 diabetes mellitus related to immune checkpoint inhibitors |
topic | Clinical Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856268/ https://www.ncbi.nlm.nih.gov/pubmed/36694808 http://dx.doi.org/10.1210/jendso/bvad002 |
work_keys_str_mv | AT fujitayasunori combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT kamitanifumika combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT yamamotomasaaki combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT fukuokahidenori combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT hirotayushi combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT nishiyamanobuharu combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT godanaho combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT okadayuko combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT inabayuiko combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT nakajimahiroki combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT kurematsuyukako combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT kaniekeitaro combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT shichihiroki combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT uraishin combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT suzukimasaki combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT yamamotonaoki combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT bandohironori combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT iguchigenzo combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT sutohirotaka combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT funakoshiyohei combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT kiyotanaomi combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT takahashiyutaka combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors AT ogawawataru combinedhypophysitisandtype1diabetesmellitusrelatedtoimmunecheckpointinhibitors |